A research team led by Prof. Ben Ko Chi-bun, Associate Professor of the PolyU Department of Applied Biology and Chemical ...
FRAMINGHAM, Mass.--(BUSINESS WIRE)--Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of investigational therapies and diagnostic assays for patients with ...
Dave Lahr, PhD, is currently leading the computational biology group at Foghorn Therapeutics, a biotech startup focused on treating diseases by correcting abnormal gene expression. In the early days ...
Panelists discuss how the expanding treatment landscape for Crohn’s disease includes multiple mechanisms of action such as ...
The rise of antimicrobial-resistant pathogens has spurred scientists to search far and wide for new drugs. And while many antimicrobial molecules have been discovered in recent years, it’s rare to ...
The first contraceptive pill available for human use in 1960 contained the estrogen mestranol, an ethinyl-estradiol precursor, in a very high concentration (150 mg), and norethynodrel, a ...
Gut microbiota as a biomarker for the efficacy of pembrolizumab in patients with advanced urothelial carcinoma treated in a prospective multicenter study. NECTIN4 RNA expression and clinical outcomes ...
Alzheon to Present Insights into Oral Valiltramiprosate/ALZ-801 Mode of Action and Clinical Efficacy at Dedicated Symposium at Alzheimer’s Association International Conference in Toronto on July 30th, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback